



# SCOPE FLUIDICS

## 2025 UPDATE

31 March 2026

# UNIQUE COMBINATION OF COMPETENCIES IN TECHNOLOGY, OPERATIONS AND FINANCIAL AREAS

## MANAGEMENT BOARD OF SCOPE FLUIDICS



**MARCIN IZYDORZAK**  
VICE PRESIDENT

- ❑ Co-founder of Scope Fluidics
- ❑ Responsible for clinical trials, IP, production and regulatory areas
- ❑ Gained experience in technology companies, scientific institutes and pharmaceutical companies



**PROF. PIOTR GARSTECKI**  
CEO

- ❑ Co-founder of Scope Fluidics
- ❑ Responsible for development of innovative technologies and building the organization
- ❑ Experience in scientific and technological projects in Poland and in the USA, specialized in soft matter physics and microfluidic technologies



**SZYMON RUTA**  
VICE PRESIDENT, CFO

- ❑ Responsible for financial division, investor relations and M&A transactions
- ❑ Experienced in managing of capital groups, cooperation with capital markets and execution of M&A transactions

# DISCLAIMERS

Niniejsza prezentacja ("Prezentacja") zawiera podstawowe informacje dotyczące Scope Fluidics S.A. („Spółka”) oraz grupy kapitałowej Scope Fluidics S.A. („Grupa”).

Prezentacja została przygotowana wyłącznie w celu przedstawienia podstawowych informacji o Grupie i jej działalności. Prezentacja nie przedstawia pełnych danych dotyczących działalności Grupy, jej kondycji finansowej, sytuacji majątkowej i prawnej, które mogą być wymagane w celu podjęcia decyzji inwestycyjnej dotyczącej Grupy lub instrumentów finansowych podmiotów do niej należących. Spółka podjęła środki w celu zapewnienia, że zaprezentowane dane są w pełni wiarygodne, jakkolwiek nie mogą i nie powinny być jako takie traktowane. Wszystkie przewidywania, opinie i projekcje zawarte w Prezentacji łącznie z projekcjami, opiniami oraz przewidywaniami Spółki zostały przygotowane w ramach wykonywania zwykłych czynności analitycznych i nie należy ich traktować jako informacji zatwierdzonych przez jakikolwiek podmiot trzeci. Mimo podjęcia środków mających na celu zapewnienie, że fakty wskazane w Prezentacji są prawdziwe, a przewidywania, opinie i prognozy są

wiarygodne i zasadne, Spółka nie weryfikowała ich kompletności ani trafności. W konsekwencji ani Spółka ani żaden z jej akcjonariuszy i doradców, ich podmiotów powiązanych, członków organów i pracowników nie ponosi odpowiedzialności, na jakiegokolwiek podstawie, za treści zawarte w Prezentacji.

Przy podejmowaniu decyzji inwestycyjnych, czy też działając w jakimkolwiek innym celu, nie należy opierać się na informacjach zawartych w Prezentacji, w tym w zakresie ich prawdziwości, rzetelności i zupełności. Żaden z wymienionych wyżej podmiotów nie uznaje swojej odpowiedzialności na jakiegokolwiek podstawie za jakiegokolwiek szkody wynikające z użycia niniejszego dokumentu i informacji w nim zawartych. Oświadczeń zawartych w Prezentacji nie należy traktować jako zapewnień lub gwarancji Spółka lub jako zobowiązań czy obietnic dotyczących przyszłych wyników finansowych czy operacyjnych Grupy. Treść Prezentacji nie stanowi ani nie powinna być traktowana jako porada inwestycyjna, prawna lub podatkowa. Odbiorca Prezentacji powinien samodzielnie uzyskać odpowiednią poradę inwestycyjną, prawną bądź podatkową.

Prezentacja nie stanowi oferty, w szczególności w rozumieniu ustawy z dnia 29 lipca 2005 roku o ofercie publicznej i warunkach wprowadzania instrumentów finansowych do zorganizowanego systemu obrotu oraz o spółkach publicznych (Dz.U. t.j. 2013.1382 z późn. zm.) lub ustawy z dnia 23 kwietnia 1964 r. kodeks cywilny (Dz.U. t.j. 2014.121 z późn. zm.), rekomendacji lub zaproszenia do zapisywania się lub zakupu obligacji. Ani Prezentacja ani żadna jej część nie stanowi jakiegokolwiek umowy lub jakiegokolwiek zobowiązania dotyczącego wykonania takiej umowy.

Spółka zastrzega sobie prawo do dokonania zmian lub uzupełniania Prezentacji w każdym momencie, jakkolwiek nie jest do tego zobowiązana, podobnie jak nie jest zobowiązana do dokonywania jakichkolwiek aktualizacji lub poprawek treści Prezentacji, ani do dostarczania dodatkowych informacji o Spółce ani Grupie.

# **VENTURE STUDIO - OUR VALUES AND VISION FOR SUCCESS**

We address **global challenges in healthcare** and develop technologies with real, global impact

We aim at **+USD 10<sup>9</sup> markets** and develop technologies that can readily be leveraged by large, multinational and global med-tech operators

We develop companies as attractive acquisition targets for global strategic investors with valuations in multiples of USD 100 mln



## Where do we want to be?

1

**By the end of 2025**  
having at least five new projects in the portfolio,  
including **at least two** in the form of **special  
purpose vehicles**

2

**By the end of 2028**  
Closing at least two  
**strategic transactions**

3

**In the period of 2029-2033**  
readiness to carry out **at least one  
strategic transaction on an annual average**

### STRATEGIC TRANSACTIONS:

1. **Sale of all shares in special purpose vehicles**  
developing breakthrough technologies to strategic industry investors
2. **Sale of part of existing or newly created shares in Special Purpose Vehicles**  
developing breakthrough technologies to strategic industry or financial investors

# KEY EVENTS & UPDATES

## FOCUS ON FINANCING DIVERSIFICATION AND SECURITY

- ✓ Strengthening negotiation position for strategic transactions and providing greater flexibility for investment opportunities:
  - ✓ PLN 64 million raised in October 2025 (share issue)
  - ✓ PLN 156,9 million in cash at the end of 2025
- ✓ Extension of the existing financing model for projects developed within subsidiaries arising from Scope Discovery (2026)



# BACTEROMIC

BACTEROMIC  
Use antimicrobials responsibly



BACTEROMIC  
Everyone has a role to play to address AMR



BACTEROMIC  
Don't let antimicrobial resistance take control




BACTEROMIC  
The Time to Act is Now



# Finally, single AST system for all infections – fast, flexible, accessible




- **Single system for PBC and Isolates**
- **Single test for actionable information** – simpler workflow and the highest information content immediate guidance for precision antibiotic therapies
- **Strong margin flexibility for both segments** driven by primary focus on very low consumable cost
- **Rapid results regardless of sample type** – patient's same-day release could save up to 1500 USD per hospitalization day
- **High-throughput and full flexibility** to adapt to changing volumes and sample types




# Two AST segments, one mission – but no solution to check all the boxes

There are two key segments: mainstream, routine infections (isolated bacteria cultures) and urgent bloodstream infections (cultured blood - PBC)



**Isolates and PBC requirements are converging,  
yet no existing AST system meets the needs of both segments**



**AST market needs future-proof, informative, rapid and cost-effective system**

**that offers synergies across isolate and PBC market segments**


# IVDR for Panel UNI2.0 – study design & results



Study performed in  
**3 external sites**  
and **internal site**



Process was monitored by  
**Clinical Research**  
**Organization**



**~1000**  
**strains tested**

## IVDR RESULTS SUMMARY



**30 antibiotics**  
present on  
the panel



**56 drug-bug**  
combinations  
can be tested



Detection of **ESBL**  
resistance  
mechanism



# Securing commercial-scale manufacturing capacity to meet future demand and effects of scale

## ANALYZER & FILLING DEVICE



### Cooperation with BIT Analytical Solutions

Germany-based OEM specialized in electronic hardware assembly

## CONSUMABLES

PILOT PRODUCTION LINE:


**~100k** panels/year



COMMERCIAL PRODUCTION LINE:


up to **~700k** panels/year

**Line validation expected in mid 2026**



# Initiating clinical presence & signing first distribution agreements

Done, ongoing and planned pilot trials in European countries.  
Planned first evaluations in USA in 2026



- Strong advantage of **true MIC values**
- **Great performance** - in line with currently used methods
- **Results faster by even 24h** (for FAST products)
- **Convenient workflow, easy to use** even for less skilled staff
- System **easy to adopt & occupies less space** in the lab

## SIGNED DISTRIBUTION AGREEMENTS

- ELTA 90 MR (Romania) 
- Mefamed (Turkey) 

## ONGOING DISCUSSIONS & NEGOTIATIONS WITH SELECTED PARTIES IN OTHER REGIONS

# Bacteromic - Clinical Advisory Board Members



## **Stephen Kidd (UK)**

The Principal Clinical Scientist of Hampshire Hospitals NHS Foundation Trust, specializing in microbiology (incl. research on antibiotic resistance) and virology, with 23+ years of experience in clinical diagnostics and rapid AST evaluations



## **Scott O'Brien (USA)**

a manager with 25+ years of experience in life sciences and diagnostics, covering areas such as R&D, marketing, commercialization, and international management (ex-SpecificDx and ex-GenMark)



## **Tiziana di Martino (IT)**

Physician and manager with over 20 years of experience in clinical practice, scientific research, and health economics, with an extensive experience in the MedTech and IVD sectors (ex-Q-Linea, ex-Accelerate)




## **Stefan Riedel (USA)**

Prof. of Pathology at Harvard Medical School and head of clinical microbiology laboratories at Beth Israel Deaconess Medical Center. A recognized authority in the fields of sepsis research and bacterial resistance.

Regulatory pathway

# Regulatory pipeline for complementary AST offering – globally



\*For selected, limited number of drug-bug pairs TTR can be 8h.

2026

2027

## Transaction Advisor: Perella Weinberg Partners (PWP)

- ▶ PWP is a leading, global, independent investment banking firm with 700+ employees across 10 offices
- ▶ The firm has advised on over USD 1 trillion in transactions, including USD 200+ billion in healthcare since 2011
- ▶ Its healthcare team includes 65+ specialists and 9 partners
- ▶ PWP has deep expertise in the AST sector, supported by work with multiple clients and numerous successful transactions






# DISCOVERY & NEW PROJECTS

# Systematic beats ad hoc

Level of Involvement



> Structured Idea Generation

> Access to Exceptional Talent

> End-to-End Venture Support


> Embedded Shared Services

> High Throughput

> Risk Diversification

> Proprietary Execution Framework

# Systematic beats ad hoc



## Life Sciences Venture Studios

### UNITED STATES



### WESTERN EUROPE


### CENTRAL EASTERN EUROPE

**SCOPE DISCOVERY**

# How we operate

Systemic selection and development of new projects



# Fellowship program

- ▶ Scope Fluidics Fellowship program launched in 2025 & continued in 2026
- ▶ 12-week hands-on program for young scientists, AI engineers, business students and postdocs
- ▶ Mentoring and support from experienced industry experts
- ▶ Top projects eligible for further support, including Proof of Concept



**From idea → concept development → final presentation**

# AI-driven platform with a life-saving device for early stroke detection



## PROBLEM

Strokes often go undetected for hours, preventing timely treatment and contributing to over **12 million stroke-related deaths annually, approx. 100 mln people at high stroke risk and 1bn at increased risk**. With a projected 32% increase, the economic impact surpasses **\$450 billion**.

1



## SOLUTION

Our device leverages AI to analyze subtle signal changes, enabling early stroke detection and tracking of hemodynamic parameters.

2



Verification of selected technologies



Prototype device – expected in 2026



Starting R&D on final device design – expected in 2027



## IMPACT

This technology empowers treatment within the critical **4.5-6 hour window, potentially preventing 80% of stroke related consequences and saving the lives of high risk patients**.

3



## MARKET OPPORTUNITY

**\$4.0**  
billion TAM

**~10.0%**  
CAGR

4

## Recognition:

winner of **MedX@Düsseldorf & Start-ups Are Us (PARP)**; selected among top 75+ startups in **Deep Tech CEE Challenge**

# Comprehensive solution for monitoring of metabolic parameters



## PROBLEM

The global prevalence of diabetes is steadily increasing, with projections indicating a significant rise, potentially reaching **643 million cases within the next five years**.

1



## SOLUTION

Early detection of metabolic syndrome risk through monitoring key biomarkers for insulin resistance and type 2 diabetes.

2



## IMPACT

Metabolic imbalance poses a significant health risk, with **1 in 10 individuals affected by diabetes and a life lost to the disease every 5 seconds**. Early detection and treatment of abnormal glycemc trends can prevent up to 60% of diabetes cases.

3



## MARKET OPPORTUNITY

**\$23.0**  
billion TAM

**20.0%**  
CAGR

4



Verification of selected technologies – planned in 2026




Pre-clinical studies to verify insulin measurement application – expected in 2026



Finalizing prototype & starting R&D for final device design – expected in 2027

Hybolic has been awarded **conditional PLN 16.1 million non-dilutive funding** Smart Path (Ścieżka SMART) by PARP with a total project budget of PLN 24.1 million.

# Financial results 2025



# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of profit or loss and other comprehensive income (income statement) [PLN thousand]

	2025	2024
<b>Revenue</b>	<b>100</b>	<b>131</b>
<b>Operating expenses</b>	<b>(47,327)</b>	<b>(32,577)</b>
Depreciation and amortisation	(2,131)	(1,512)
Raw materials and consumables used	(3,738)	(1,312)
External services	(16,130)	(11,417)
Taxes and charges	(355)	(160)
Wages and salaries	(19,842)	(14,456)
Social security and other employee benefits	(2,654)	(2,264)
Other expenses by nature	(2,477)	(1,456)
<b>Gross loss</b>	<b>(47,227)</b>	<b>(32,446)</b>
Gain (loss) on disposal of subsidiary	0	109,541
Other income (expenses)	(55)	(41)
<b>Operating profit (loss)</b>	<b>(47,282)</b>	<b>77,054</b>
Finance income	4,845	8,573
Finance costs	(3,616)	(231)
<b>Profit (loss) before tax</b>	<b>(46,053)</b>	<b>85,396</b>
Income tax	(311)	(19,975)
<b>Net profit (loss)</b>	<b>(46,364)</b>	<b>65,421</b>

Operating expenses at the Group rose by PLN 14.8 million year on year, driven mainly by:

- increase in the cost of external services (up by PLN 4.7 million), and
- increase in wages and salaries (up by PLN 5.4 million).

# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of profit or loss and other comprehensive income (income statement) [PLN thousand]

	2025	2024
<b>Revenue</b>	<b>100</b>	<b>131</b>
<b>Operating expenses</b>	<b>(47,327)</b>	<b>(32,577)</b>
Depreciation and amortisation	(2,131)	(1,512)
Raw materials and consumables used	(3,738)	(1,312)
<b>External services</b>	<b>(16,130)</b>	<b>(11,417)</b>
Taxes and charges	(355)	(160)
Wages and salaries	(19,842)	(14,456)
Social security and other employee benefits	(2,654)	(2,264)
Other expenses by nature	(2,477)	(1,456)
<b>Gross loss</b>	<b>(47,227)</b>	<b>(32,446)</b>
Gain (loss) on disposal of subsidiary	0	109,541
Other income (expenses)	(55)	(41)
<b>Operating profit (loss)</b>	<b>(47,282)</b>	<b>77,054</b>
Finance income	4,845	8,573
Finance costs	(3,616)	(231)
<b>Profit (loss) before tax</b>	<b>(46,053)</b>	<b>85,396</b>
Income tax	(311)	(19,975)
<b>Net profit (loss)</b>	<b>(46,364)</b>	<b>65,421</b>

The higher overall cost of external services was largely attributable to increased expenses related to services within Scope Discovery, as well as the cost of services incurred at Hybolic and Edocera.

# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of profit or loss and other comprehensive income (income statement) [PLN thousand]

	2025	2024
<b>Revenue</b>	<b>100</b>	<b>131</b>
<b>Operating expenses</b>	<b>(47,327)</b>	<b>(32,577)</b>
Depreciation and amortisation	(2,131)	(1,512)
Raw materials and consumables used	(3,738)	(1,312)
External services	(16,130)	(11,417)
Taxes and charges	(355)	(160)
<b>Wages and salaries</b>	<b>(19,842)</b>	<b>(14,456)</b>
Social security and other employee benefits	(2,654)	(2,264)
Other expenses by nature	(2,477)	(1,456)
<b>Gross loss</b>	<b>(47,227)</b>	<b>(32,446)</b>
Gain (loss) on disposal of subsidiary	0	109,541
Other income (expenses)	(55)	(41)
<b>Operating profit (loss)</b>	<b>(47,282)</b>	<b>77,054</b>
Finance income	4,845	8,573
Finance costs	(3,616)	(231)
<b>Profit (loss) before tax</b>	<b>(46,053)</b>	<b>85,396</b>
Income tax	(311)	(19,975)
<b>Net profit (loss)</b>	<b>(46,364)</b>	<b>65,421</b>

The overall increase in wages and salaries was close to PLN 5.4 million, comprising:

- PLN 3.6 million increase on the remeasurement of phantom share liabilities,
- PLN 1.8 million increase in costs under employment and other contracts for the provision of work.

The average headcount in 2025 was 86, vs 63 in 2024.

# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of profit or loss and other comprehensive income (income statement) [PLN thousand]

	2025	2024
<b>Revenue</b>	<b>100</b>	<b>131</b>
<b>Operating expenses</b>	<b>(47,327)</b>	<b>(32,577)</b>
Depreciation and amortisation	(2,131)	(1,512)
Raw materials and consumables used	(3,738)	(1,312)
External services	(16,130)	(11,417)
Taxes and charges	(355)	(160)
Wages and salaries	(19,842)	(14,456)
Social security and other employee benefits	(2,654)	(2,264)
Other expenses by nature	(2,477)	(1,456)
<b>Gross loss</b>	<b>(47,227)</b>	<b>(32,446)</b>
Gain (loss) on disposal of subsidiary	0	109,541
Other income (expenses)	(55)	(41)
<b>Operating profit (loss)</b>	<b>(47,282)</b>	<b>77,054</b>
<b>Finance income</b>	<b>4,845</b>	<b>8,573</b>
Finance costs	(3,616)	(231)
<b>Profit (loss) before tax</b>	<b>(46,053)</b>	<b>85,396</b>
Income tax	(311)	(19,975)
<b>Net profit (loss)</b>	<b>(46,364)</b>	<b>65,421</b>

The Group recognised the following income from invested cash for the year ended 2025:

- PLN 3.2 million of interest income (vs 3.2 million in 2024),
- PLN 1.6 million of gains arising from the remeasurement of investment fund units (vs 1.3 million in 2024).

# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of profit or loss and other comprehensive income (income statement) [PLN thousand]

	2025	2024
<b>Revenue</b>	<b>100</b>	<b>131</b>
<b>Operating expenses</b>	<b>(47,327)</b>	<b>(32,577)</b>
Depreciation and amortisation	(2,131)	(1,512)
Raw materials and consumables used	(3,738)	(1,312)
External services	(16,130)	(11,417)
Taxes and charges	(355)	(160)
Wages and salaries	(19,842)	(14,456)
Social security and other employee benefits	(2,654)	(2,264)
Other expenses by nature	(2,477)	(1,456)
<b>Gross loss</b>	<b>(47,227)</b>	<b>(32,446)</b>
Gain (loss) on disposal of subsidiary	0	109,541
Other income (expenses)	(55)	(41)
<b>Operating profit (loss)</b>	<b>(47,282)</b>	<b>77,054</b>
Finance income	4,845	8,573
<b>Finance costs</b>	<b>(3,616)</b>	<b>(231)</b>
<b>Profit (loss) before tax</b>	<b>(46,053)</b>	<b>85,396</b>
Income tax	(311)	(19,975)
<b>Net profit (loss)</b>	<b>(46,364)</b>	<b>65,421</b>

The increase in finance costs in 2025 was attributable to foreign exchange losses realised by the Group on foreign currency transactions.

# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of financial position (balance sheet) [PLN thousand]

	31 Dec 2025	31 Dec 2024
<b>Non-current assets</b>	<b>29,265</b>	<b>16,417</b>
<b>Current assets, including:</b>	<b>166,670</b>	<b>156,453</b>
<i>Cash in hand and at banks</i>	93,153	128,971
<i>Investment fund units</i>	63,772	22,192
<i>Other current assets</i>	9,745	5,290
<b>Total assets</b>	<b>195,935</b>	<b>172,870</b>
<b>Equity</b>	<b>162,431</b>	<b>146,351</b>
<b>Liabilities and provisions for liabilities</b>	<b>33,504</b>	<b>26,519</b>
<b>Total equity and liabilities</b>	<b>195,935</b>	<b>172,870</b>

The significant year-on-year increase in non-current assets of PLN 12.9 million was mainly attributable to:

- purchase of machinery and equipment making up the Bacteromic production line (PLN 4.5 million),
- capitalised development costs at Bacteromic (PLN 8.1 million).

# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of financial position (balance sheet) [PLN thousand]

	31 Dec 2025	31 Dec 2024
<b>Non-current assets</b>	<b>29,265</b>	<b>16,417</b>
<b>Current assets, including:</b>	<b>166,670</b>	<b>156,453</b>
<i>Cash in hand and at banks</i>	93,153	128,971
<i>Investment fund units</i>	63,772	22,192
<i>Other current assets</i>	9,745	5,290
<b>Total assets</b>	<b>195,935</b>	<b>172,870</b>
<b>Equity</b>	<b>162,431</b>	<b>146,351</b>
<b>Liabilities and provisions for liabilities</b>	<b>33,504</b>	<b>26,519</b>
<b>Total equity and liabilities</b>	<b>195,935</b>	<b>172,870</b>

The largest component of current assets, amounting in aggregate to PLN 156.9 million, comprises cash and cash equivalents.

# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of financial position (balance sheet) [PLN thousand]

	31 Dec 2025	31 Dec 2024
<b>Non-current assets</b>	<b>29,265</b>	<b>16,417</b>
<b>Current assets, including:</b>	<b>166,670</b>	<b>156,453</b>
<i>Cash in hand and at banks</i>	93,153	128,971
<i>Investment fund units</i>	63,772	22,192
<i>Other current assets</i>	9,745	5,290
<b>Total assets</b>	<b>195,935</b>	<b>172,870</b>
<b>Equity</b>	<b>162,431</b>	<b>146,351</b>
<b>Liabilities and provisions for liabilities</b>	<b>33,504</b>	<b>26,519</b>
<b>Total equity and liabilities</b>	<b>195,935</b>	<b>172,870</b>

The increase in equity was driven by the issue of new shares in late October 2025.

# Scope Fluidics consolidated financial statements at 31 Dec 2025

Statement of financial position (balance sheet) [PLN thousand]

	31 Dec 2025	31 Dec 2024
<b>Non-current assets</b>	<b>29,265</b>	<b>16,417</b>
<b>Current assets, including:</b>	<b>166,670</b>	<b>156,453</b>
<i>Cash in hand and at banks</i>	93,153	128,971
<i>Investment fund units</i>	63,772	22,192
<i>Other current assets</i>	9,745	5,290
<b>Total assets</b>	<b>195,935</b>	<b>172,870</b>
<b>Equity</b>	<b>162,431</b>	<b>146,351</b>
<b>Liabilities and provisions for liabilities</b>	<b>33,504</b>	<b>26,519</b>
<b>Total equity and liabilities</b>	<b>195,935</b>	<b>172,870</b>

Liabilities and provisions for liabilities rose by approximately PLN 7.0 million year on year, mainly on account of:

- increase in trade payables at Bacteromic (up by PLN 2.9 million),
- increase in phantom share liabilities for Bacteromic (up by PLN 5.0 million).



# Q&A session



# THANK YOU

**INVESTOR RELATIONS**

[relacjinwestorskie@scopefluidics.com](mailto:relacjinwestorskie@scopefluidics.com)